β-Glucan attenuates loss of barrier dysfunction induced by neutrophils from septic patients. Change in monolayer resistance at 30 minutes, 60 minutes, and 180 minutes comparing neutrophil samples from all patients with sepsis (sepsis), samples obtained once sepsis had resolved (resolution), and samples of septic patients’ neutrophils treated with β-glucan (glucan). Groups were analyzed using two-way analysis of variance with Holm–Sidak post-hoc analysis. Values presented as mean ± standard error of the mean. Treatment of neutrophils from septic patients with β-glucan led to an effect upon barrier function that was similar to that induced by neutrophils obtained upon resolution of sepsis; both groups caused less barrier dysfunction than untreated neutrophils from septic patients. *P <0.05 vs. sepsis.